Loading

Active Biomarkers and Cynbiose sign a comarketing agreement

Active Biomarkers and Cynbiose sign a comarketing agreement

Active Biomarkers and Cynbiose are strengthening their more than 10 years collaboration with the signature of a business and comarketing agreement, offering their partners a unique combination of services to accelerate their drug developments. Check…

Read More
Active Biomarkers awarded GCLP Accreditation

Active Biomarkers awarded GCLP Accreditation

Active Biomarkers laboratories have been granted the Good Clinical Laboratory Practices (GCLP) Accreditation following an external assessment by Qualogy Ltd. Check our Press Relase for more information.  

Read More
14th EBF Open Symposium

14th EBF Open Symposium

EBF Annual Open Symposium is a landmark for bioanalytical discussions in EU. After almost two years due to the COVID pandemic, our scientists are happy to go back to Barcelona.  And we will be presenting…

Read More
Immunotherapies and Innovations for Infectious Diseases - I4ID

Immunotherapies and Innovations for Infectious Diseases - I4ID

Meet our team and discover our scientific poster at the 5th I4ID annual conference!

Read More
Boston Biotechnology Summit 2021
  • September 30, 2021
  • Virtual Conference
  • Events

Boston Biotechnology Summit 2021

Active Biomarkers together with its preferred partners Banook Group and Phinc Development is honoured to support the 5th edition of the Boston Biotechnology Summit. An exclusive Trans-Atlantic bridge designed to foster innovative synergies between biotech and…

Read More
Alongside its senior managers, Turenne Santé acquires ABL Lyon from Institut Mérieux, creating a new entity named Active Biomarkers.

Alongside its senior managers, Turenne Santé acquires ABL Lyon from Institut Mérieux, creating a new entity named Active Biomarkers.

ABL Lyon, a subsidiary of Institut Mérieux and a benchmark laboratory in biomarker analysis, is acquired by Turenne Santé via its private equity fund Capital Santé 2. Alongside its general manager, Marc Essodaigui, and the…

Read More